SG11201912864SA - Multi-specific antibodies and methods of making and using thereof - Google Patents
Multi-specific antibodies and methods of making and using thereofInfo
- Publication number
- SG11201912864SA SG11201912864SA SG11201912864SA SG11201912864SA SG11201912864SA SG 11201912864S A SG11201912864S A SG 11201912864SA SG 11201912864S A SG11201912864S A SG 11201912864SA SG 11201912864S A SG11201912864S A SG 11201912864SA SG 11201912864S A SG11201912864S A SG 11201912864SA
- Authority
- SG
- Singapore
- Prior art keywords
- making
- methods
- specific antibodies
- antibodies
- specific
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762524557P | 2017-06-25 | 2017-06-25 | |
PCT/US2018/039156 WO2019005639A2 (en) | 2017-06-25 | 2018-06-22 | Multi-specific antibodies and methods of making and using thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201912864SA true SG11201912864SA (en) | 2020-01-30 |
Family
ID=64742644
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201912864SA SG11201912864SA (en) | 2017-06-25 | 2018-06-22 | Multi-specific antibodies and methods of making and using thereof |
Country Status (11)
Country | Link |
---|---|
US (1) | US11787863B2 (en) |
EP (1) | EP3645049A4 (en) |
JP (1) | JP7399852B2 (en) |
KR (1) | KR20200092301A (en) |
CN (4) | CN116948035A (en) |
AU (1) | AU2018295118A1 (en) |
CA (1) | CA3068045A1 (en) |
IL (1) | IL271257A (en) |
RU (1) | RU2020102662A (en) |
SG (1) | SG11201912864SA (en) |
WO (1) | WO2019005639A2 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7474193B2 (en) * | 2017-06-25 | 2024-04-24 | システィミューン, インク. | Multispecific antibodies and methods for making and using same |
WO2019005642A1 (en) * | 2017-06-25 | 2019-01-03 | Systimmune, Inc. | Methods of making and using guidance and navigation control proteins |
CN116535508A (en) * | 2017-06-25 | 2023-08-04 | 西雅图免疫公司 | anti-PD-L1 antibodies and methods of making and using the same |
JP2021519072A (en) * | 2018-03-27 | 2021-08-10 | システィミューン, インク.Systimmune, Inc. | Guidance and navigation control proteins and their production and usage |
TW202132352A (en) * | 2019-11-06 | 2021-09-01 | 美商西雅圖免疫公司 | Guidance and navigation control proteins and method of making and using thereof |
EP3988568A1 (en) * | 2020-10-21 | 2022-04-27 | Numab Therapeutics AG | Combination treatment |
WO2023198635A1 (en) * | 2022-04-11 | 2023-10-19 | Astrazeneca Ab | T cell binding proteins |
CN116143934B (en) * | 2023-03-21 | 2023-07-25 | 诺赛联合(北京)生物医学科技有限公司 | Stem cell exosome extraction kit and application thereof |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002092771A2 (en) | 2001-05-11 | 2002-11-21 | Ludwig Institute For Cancer Research | Specific binding proteins and uses thereof |
EP3150630A1 (en) * | 2002-09-27 | 2017-04-05 | Xencor Inc. | Optimized fc variants and methods for their generation |
AU2006262232A1 (en) | 2005-06-20 | 2007-01-04 | Medarex, Inc. | CD19 antibodies and their uses |
CA2705539A1 (en) * | 2007-11-13 | 2009-05-22 | Evec Inc. | Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same |
US9365644B2 (en) | 2008-04-23 | 2016-06-14 | Epitomics, Inc. | Anti-TNFα antibody |
CA2756244A1 (en) | 2009-04-02 | 2010-10-07 | Roche Glycart Ag | Multispecific antibodies comprising full length antibodies and single chain fab fragments |
BRPI1007602A2 (en) * | 2009-05-27 | 2016-02-16 | Hoffmann La Roche | "tri or tetraspecific antibody, method for preparing a trispecific or tetraspecific antibody, host cell, composition, pharmaceutical composition and method for treating a patient in need of therapy" |
GB201020995D0 (en) * | 2010-12-10 | 2011-01-26 | Bioinvent Int Ab | Biological materials and uses thereof |
WO2013070565A1 (en) * | 2011-11-07 | 2013-05-16 | Medimmune, Llc | Multispecific and multivalent binding proteins and uses thereof |
KR102134088B1 (en) * | 2012-08-24 | 2020-07-14 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis |
US9732150B2 (en) * | 2013-03-14 | 2017-08-15 | Alderbio Holdings Llc | Therapeutic use of antibodies to HGF |
CA2914829A1 (en) | 2013-06-26 | 2014-12-31 | Numab Ag | Novel antibody frameworks |
EP3406633B1 (en) * | 2013-07-25 | 2022-03-02 | Cytomx Therapeutics Inc. | Multispecific antibodies, multispecific activatable antibodies and methods of using the same |
US20160368987A1 (en) * | 2013-10-25 | 2016-12-22 | Numab Ag | Bispecific constructs and their use in the treatment of various diseases |
EP3107569A4 (en) | 2014-02-20 | 2018-02-21 | Alder Biopharmaceuticals, Inc. | Anti-acth antibodies and use thereof |
UA117289C2 (en) * | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Multispecific antibodies |
EP3237449A2 (en) | 2014-12-22 | 2017-11-01 | Xencor, Inc. | Trispecific antibodies |
JP6640232B2 (en) * | 2015-02-06 | 2020-02-05 | ユニバーシティ オブ メリーランド,ボルチモア | Quadruple-specific octameric binders and antibodies to Clostridium difficile against toxin A and toxin B for the treatment of Clostridium difficile infection |
CN104829733B (en) * | 2015-05-25 | 2018-06-05 | 广州百暨基因科技有限公司 | The Chimeric antigen receptor and preparation method and application that antigen-binding unit is stablized |
MA42821A (en) * | 2015-09-15 | 2018-07-25 | Amgen Inc | TETRAVALENT TETRASPECIFIC AND BISPECIFIC BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF |
JP7474193B2 (en) | 2017-06-25 | 2024-04-24 | システィミューン, インク. | Multispecific antibodies and methods for making and using same |
WO2019005642A1 (en) * | 2017-06-25 | 2019-01-03 | Systimmune, Inc. | Methods of making and using guidance and navigation control proteins |
JP2021519072A (en) * | 2018-03-27 | 2021-08-10 | システィミューン, インク.Systimmune, Inc. | Guidance and navigation control proteins and their production and usage |
-
2018
- 2018-06-22 CA CA3068045A patent/CA3068045A1/en active Pending
- 2018-06-22 RU RU2020102662A patent/RU2020102662A/en unknown
- 2018-06-22 CN CN202310922275.XA patent/CN116948035A/en active Pending
- 2018-06-22 CN CN202310141321.2A patent/CN116199785A/en active Pending
- 2018-06-22 AU AU2018295118A patent/AU2018295118A1/en active Pending
- 2018-06-22 JP JP2020520429A patent/JP7399852B2/en active Active
- 2018-06-22 EP EP18825293.6A patent/EP3645049A4/en active Pending
- 2018-06-22 SG SG11201912864SA patent/SG11201912864SA/en unknown
- 2018-06-22 US US16/615,122 patent/US11787863B2/en active Active
- 2018-06-22 CN CN202310141062.3A patent/CN116041530A/en active Pending
- 2018-06-22 KR KR1020207002328A patent/KR20200092301A/en not_active Application Discontinuation
- 2018-06-22 WO PCT/US2018/039156 patent/WO2019005639A2/en unknown
- 2018-06-22 CN CN201880039401.4A patent/CN110831973B/en active Active
-
2019
- 2019-12-08 IL IL271257A patent/IL271257A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN116041530A (en) | 2023-05-02 |
CN116199785A (en) | 2023-06-02 |
JP2020530777A (en) | 2020-10-29 |
CN110831973B (en) | 2023-08-15 |
KR20200092301A (en) | 2020-08-03 |
EP3645049A2 (en) | 2020-05-06 |
JP7399852B2 (en) | 2023-12-18 |
EP3645049A4 (en) | 2021-06-30 |
WO2019005639A3 (en) | 2019-02-07 |
CN116948035A (en) | 2023-10-27 |
CA3068045A1 (en) | 2019-01-03 |
AU2018295118A1 (en) | 2020-02-06 |
IL271257A (en) | 2020-01-30 |
US20220002406A1 (en) | 2022-01-06 |
WO2019005639A2 (en) | 2019-01-03 |
RU2020102662A (en) | 2021-07-27 |
US11787863B2 (en) | 2023-10-17 |
CN110831973A (en) | 2020-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI3618863T1 (en) | Anti-tigit antibodies and methods of use thereof | |
ZA201906730B (en) | Anti-trem2 antibodies and methods of use thereof | |
EP3645050A4 (en) | Multi-specific antibodies and methods of making and using thereof | |
EP3645742A4 (en) | Anti-ror1 antibodies and methods of making and using thereof | |
IL271260A (en) | Multi-specific antibodies and methods of making and using thereof | |
HK1251969A1 (en) | Anti-her2 antibodies and methods of use | |
IL271257A (en) | Multi-specific antibodies and methods of making and using thereof | |
HK1254743A1 (en) | Novel anti-claudin antibodies and methods of use | |
IL252837B (en) | Fcrn antibodies and methods of use thereof | |
IL275070A (en) | Fcrn antibodies and methods of use thereof | |
EP3313993A4 (en) | Anti-apobec3 antibodies and methods of making and using | |
IL274221A (en) | Anti-apoc3 antibodies and methods of use thereof | |
RS64530B1 (en) | Anti-bed bug monoclonal antibodies and methods of making and uses thereof | |
ZA202002144B (en) | Antibodies and methods of use | |
IL271346A (en) | Bispecific antibodies and methods of making and using thereof | |
IL275493A (en) | Antibodies to centrin-1, methods of making, and uses thereof | |
AU2015901092A0 (en) | PAT-SM3 related antibodies and methods of making and using same | |
AU2014901301A0 (en) | PAT-SM3 related antibodies and methods of making and using same |